StockData

Alvotech vs Krystal Biotech

ALVO and KRYS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALVO and KRYS compare

Krystal Biotech grew revenue faster over the last twelve months (22.6% versus 19.7% for Alvotech).

Krystal Biotech scores higher on the StockData Score (11 against 3 for Alvotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALVOKRYS
Size and price
Market cap–$8.8B
Share price$4.37$298.55
Change, 1 year−20.4%44.8%
Change, 5 years−55.8%650%
Beta (5Y)0.371.01
Employees1,000295
StockData Score
Total score311 (better)
Valuation score01 (better)
Growth score2 (better)1
Performance score03 (better)
Health score16 (better)
Dividend score00
Valuation
P/E–37.4×
P/S–20.1×
P/B–6.5×
EV/EBITDA–40.4×
P/FCF–34.3×
FCF yield–2.9%
Fair value–$195.99
Margin of safety–−52.3%
Growth
Revenue growth (TTM)19.7%22.6% (better)
Revenue growth, 5Y average54.5%–
Net income growth (TTM)–64.6%
EPS growth (TTM)–62.2%
Profitability
Gross margin59.8%–
Operating margin13.3%44.9% (better)
Net margin–54.8%
FCF margin−19.6%58.5% (better)
Return on equity–20.1%
Return on invested capital–45.3%
Financial health
Debt / equity–0.00
Net debt / EBITDA10.02–
Interest coverage0.5×–
Current ratio1.658.32 (better)
Altman Z-score–39.06
Piotroski F-score–6
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–102%
Held by insiders67.7%17.1%
Insider net buying, 12 months–−$105M
Short interest, % of float–12.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.